ReShape Lifesciences Inc (NASDAQ:RSLS) currently has a daily average trading volume of 5.39M but it saw 73964181 shares traded in last market. With a market cap of 1.49M USD, the company’s current market price of $0.45 came falling about -71.70 while comparing to the previous closing price of $1.59. In past 52 weeks, the stock remained buoying in the range of price level as high as $29.00 and as low as $0.34. In the recent trading on the day, stock has struck highest price mark of $0.4282 while lowest mark touched by it was $0.7018.
Taking a look at 20-day trading activity of ReShape Lifesciences Inc (RSLS) gives us an average price of $0.6677, while its current price level is -98.45% below from 52-week high level whereas it is 30.64% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.7857 while that of 200 days or SMA-200 reads an average of $6.2422. A closer look into the stock’s movement over the week reveals that its volatility is standing at 85.37% during that period while stretching the period over a month that decreases to 30.32%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.85 which implies that the stock is in neutral territory.
Over the week, RSLS’s stock price is moving -4.72% down while it is -55.45% when we observe its performance for the past one month. Year-to-date it is -89.91% down and over the past year, the stock is showing a downside performance of -95.23%.
The company is expected to be releasing its next quarterly report on 2024-Nov-13, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, ReShape Lifesciences Inc’s total number of outstanding shares is 3.31M with 14.01% of that held by the insiders while 16.64% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -451.85% and return on equity (ROE) at -309.28%. Stock’s beta reads 1.27. Stock has a price to book (P/B) ratio of 0.21 while price to sale or P/S ratio amounts to 0.18. Its return on asset (ROA) is -105.15% on average.
